Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE

NCT02625155 is registered in ClinicalTrials.gov with InSource Diagnostics as lead sponsor.

NCT NCT02625155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02625155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE
Lead sponsor
InSource Diagnostics
Phase
Phase 4
Overall status
Unknown status
Start date
December 31, 2015
Completion date
Not reported
Enrollment
14,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

target drug-related adverse events